Oculis Holding AG
XNAS:OCS 11:30:27 AM EDT
| Market Cap (Intraday) | 1.74B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $30.21 |
| 50-Day MA | $27.33 |
| 200-Day MA | $22.68 |
Oculis Holding AG Stock, XNAS:OCS
Bahnhofstrasse 7, Bat D 3e Route J-D. Colladon, Zug, Zug 6300
Switzerland
Phone: +41.58.810.01.82
Number of Employees: 49
Description
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.